The role of hyperleptinaemia and low values of interleukin 10 in de novo DSA production after kidney transplantation

被引:0
|
作者
Dedinska, Ivana [1 ,2 ,3 ,5 ]
Kleinova, Patricia [1 ,2 ,3 ]
Machalekova, Katarina [4 ]
Granak, Karol [1 ,2 ,3 ]
Vnucak, Matej [1 ,2 ,3 ]
Beliancinova, Monika [1 ,2 ,3 ]
机构
[1] Univ Hosp Martin, Transplant Ctr, Martin, Slovakia
[2] Comenius Univ, Jessenius Fac Med, Bratislava, Slovakia
[3] Univ Hosp Martin, Dept Internal Dis 1, Martin, Slovakia
[4] St Elizabeth Canc Inst, Dept Pathol, Bratislava, Slovakia
[5] Univ Hosp Martin, Transplant Ctr, Kollarova 2, Martin 03601, Slovakia
关键词
Leptin; IL-10; Protocol biopsy; Kidney transplantation; LEPTIN LEVELS; BODY-FAT; POLYMORPHISMS; ADIPONECTIN; ACTIVATION; DISEASE; WEIGHT; IL-10; ALPHA; INDEX;
D O I
10.1016/j.trim.2023.101982
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: White adipose tissue secretes a number of peptide hormones. The aim of this paper was to determine the role of leptin, adiponectin and interleukin-10 and interleukin-6 on the development of graft rejection in protocol biopsy after kidney transplantation. Methods: In a prospective analysis (n = 104), we monitored the values of leptin, adiponectin, IL -6, and IL -10 prior to the transplantation and in the 3rd month after the transplantation. The protocol biopsy of the graft was performed in the 3rd month after the transplantation. The group was divided into the following according to the biopsy result: negative result, IFTA 1, borderline, and DSA positive. Results: After adjusting for the differences in the baseline recipient and donor characteristics, we identified the hyperleptinaemia baseline (HR = 2.0444, P = 0.0341) and month 3 (HR = 49.8043, P < 0.0001) as independent risk factors for borderline changes in the protocol biopsy. The hyperleptinaemia baseline (HR = 7.4979, P = 0.0071) and month 3 (HR = 9.7432, P = 0.0057) are independent risk factors for de novo DSA positivity. A low value of IL -10 month 3 is a risk factor for de novo DSA positivity (HR = 3.0746, P = 0.0388). Conclusions: Higher leptin levels and low values of IL -10 might play a role in rejection and de novo DSA production.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Evaluation of de novo donor specific antibodies after kidney transplantation in the era of donor-derived cell-free DNA
    Tian, Yuan
    Frischknecht, Lukas
    Mallone, Anna
    Roessler, Fabian
    Schachtner, Thomas
    Nilsson, Jakob
    FRONTIERS IN IMMUNOLOGY, 2025, 15
  • [42] Incidence of Delayed Graft Function and Wound Healing Complications After Deceased-Donor Kidney Transplantation Is not Affected by De Novo Everolimus
    Albano, Laetitia
    Berthoux, Francois
    Moal, Marie-Christine
    Rostaing, Lionel
    Legendre, Christophe
    Genin, Robert
    Toupance, Olivier
    Moulin, Bruno
    Merville, Pierre
    Rerolle, Jean-Philippe
    Bayle, Francois
    Westeel, Pierre Francois
    Glotz, Denis
    Kossari, Niloufar
    Lefrancois, Nicole
    Charpentier, Bernard
    Blanc, Anne-Sandrine
    Di Giambattista, Fabienne
    Dantal, Jacques
    TRANSPLANTATION, 2009, 88 (01) : 69 - 76
  • [43] Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation
    Ashimine, Satoshi
    Watarai, Yoshihiko
    Yamamoto, Takayuki
    Hiramitsu, Takahisa
    Tsujita, Makoto
    Nanmoku, Koji
    Goto, Norihiko
    Takeda, Asami
    Katayama, Akio
    Uchida, Kazuharu
    Kobayashi, Takaaki
    KIDNEY INTERNATIONAL, 2014, 85 (02) : 425 - 430
  • [44] Complement-mediated renal diseases after kidney transplantation-current diagnostic and therapeutic options in de novo and recurrent diseases
    Fedaey Abbas
    Mohsen El Kossi
    Jon Jin Kim
    Ihab Sakr Shaheen
    Ajay Sharma
    Ahmed Halawa
    World Journal of Transplantation, 2018, 8 (06) : 203 - 219
  • [45] Pediatric Kidney Transplantation Followed by De Novo Therapy With Everolimus, Low-Dose Cyclosporine A, and Steroid Elimination: 3-Year Data
    Pape, Lars
    Lehner, Frank
    Blume, Cornelia
    Ahlenstiel, Thurid
    TRANSPLANTATION, 2011, 92 (06) : 658 - 662
  • [46] Which is more important for predicting de novo DSA production in donor-sensitized kidney transplant recipients, B-cell epitope or T-cell epitope analysis?
    Ashimine, Satoshi
    Sakamoto, Shintaro
    Tomosugi, Toshihide
    Spierings, Eric
    Niemann, Matthias
    Shizuku, Masato
    Okada, Manabu
    Miwa, Yuko
    Iwasaki, Kenta
    Hiramitsu, Takahisa
    Goto, Norihiko
    Narumi, Shunji
    Watarai, Yoshihiko
    Ishiyama, Kohei
    Kobayashi, Takaaki
    HUMAN IMMUNOLOGY, 2024, 85 (06)
  • [47] Safety and metabolic advantages of steroid withdrawal after 6 months posttransplant in de novo kidney transplantation: A 1-year prospective cohort study
    Bang, Jun B.
    Oh, Chang-Kwon
    Kim, Yu S.
    Kim, Sung H.
    Yu, Hee C.
    Kim, Chan-Duck
    Ju, Man Ki
    So, Byung J.
    Lee, Sang Ho
    Han, Sang Y.
    Jung, Cheol W.
    Kim, Joong K.
    Ahn, Hyung J.
    Lee, Su H.
    Jeon, Ja Y.
    IMMUNITY INFLAMMATION AND DISEASE, 2022, 10 (03)
  • [48] De novo cancer avoidance after renal transplantation: A case-control study on low-dose sirolimus combined with a calcineurin inhibitor
    Chen, Kuo-Hsin
    Lee, Chih-Yuan
    Wu, Fe-Lin Lin
    Yang, Ching-Yao
    Yeh, Chi-Chuan
    Hu, Rey-Heng
    Tsai, Meng-Kun
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2015, 114 (06) : 526 - 531
  • [49] De novo noncutaneous malignancies after kidney transplantation are associated with an increased risk of graft failure: results from a time-dependent analysis on 672 patients
    Cena, Tiziana
    Musetti, Claudio
    Quaglia, Marco
    Magnani, Corrado
    Stratta, Piero
    Bagnardi, Vincenzo
    Cantaluppi, Vincenzo
    TRANSPLANT INTERNATIONAL, 2016, 29 (10) : 1085 - 1093
  • [50] The Role of Immunoglobulin-G Subclasses and C1q in De Novo HLA-DQ Donor-Specific Antibody Kidney Transplantation Outcomes
    Freitas, Maria Cecilia S.
    Rebellato, Lorita M.
    Ozawa, Miyuki
    Anh Nguyen
    Sasaki, Nori
    Everly, Matthew
    Briley, Kimberly P.
    Haisch, Carl E.
    Bolin, Paul
    Parker, Karen
    Kendrick, William T.
    Kendrick, Scott A.
    Harland, Robert C.
    Terasaki, Paul I.
    TRANSPLANTATION, 2013, 95 (09) : 1113 - 1119